|
Today's Headlines
There were approximately 36.1 million men and women older than age 19 years who suffered with IBS in the 7 major pharmaceutical markets in 2014. But the current IBS treatment market is naïve and underpenetrated, with only 4 products indicated for IBS in these 7 markets. » What's in the pipeline?
|
|
In a move widely seen as a way to better compete with the other major chain drugstores, Rite Aid Corp. has announced an agreement on Feb. 11 to buy the pharmacy benefits manager (PBM) EnvisionRx for about $2 billion. » Read more
|
Continuing Education
This month and next month pharmacists will be able to learn about the latest developments in diabetes treatment and management. Pharmacists can earn up to 4 hours of CPE credit with two monthly knowledge-based activities from the University of Connecticut School of Pharmacy and Drug Topics.
The goal of this month's activity is to discuss new and emerging medications for the treatment of diabetes.
Read/print the article: Click here
Take the test: Click here to log in with the Session Code 15DT15-WKX27.
Announcement: Our CE activities have moved to a new learning management system to better serve you. The login to the Online CE Center is
https://web2.uconn.edu/pharmacyce/login.php. All current user registration information has been uploaded for your convenience. Current users do not need to register. To review your registration page to ensure the data is up to date or to register, go to https://web2.uconn.edu/pharmacyce/program_register.php. For a full list of courses, go to http://pharmacy.uconn.edu/academics/ce/drug-topics-and-uconn-ce/
|
|
EDITOR'S PICK
Catamaran is the latest PBM to cut a deal for lower-priced hepatitis C treatments for its customers. At the beginning of February, Catamaran added Gilead Sciences’ hepatitis C treatments, Harvoni and Sovaldi, to its national and value formularies, making these drug therapies the exclusive options for patients with hepatitis C. » Details.
|
|
|
Like
Tweet
